Phase II data suggest new drug could unlock shorter TB treatment

New data from a phase II trial showed that sorfequiline showed greater activity against drug-susceptible TB compared to existing treatments at 8 weeks in addition to a more favorable safety profile. These results also demonstrated enough evidence to move into a phase III trial which is planned to be tested in both drug susceptible and drug resistant TB patients, giving hope for a new, shorter treatment for many suffering from TB. Read more here